MSA
LAB icon

Mason Street Advisors’s Standard BioTools LAB Stock Holding History

Mason Street Advisors’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-151,408
Closed -$2.64M – 1767
2013
Q2 		$2.64M Buy
+151,408
New +$2.66M 0.03% 585

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mason Street Advisors's LAB Position: Q3 2013 in Review

Mason Street Advisors sold out of Standard BioTools (LAB) in Q3 2013, closing a stake of 151,408 shares — an estimated $2.64M sold.

Mason Street Advisors first reported a position in LAB in Q2 2013 and held it in 1 quarter. The position peaked at $2.64M in Q2 2013. 89 funds tracked by Wall St. Rank hold LAB as of Q3 2013.

  • Mason Street Advisors reported no remaining Standard BioTools position as of Q3 2013 after selling out during the quarter.
  • Mason Street Advisors sold 151,408 Standard BioTools shares in Q3 2013, an estimated $2.64M.
  • Mason Street Advisors first reported a position in Standard BioTools in Q2 2013 and held it in 1 quarter.
  • Mason Street Advisors's Standard BioTools position peaked at $2.64M in Q2 2013.
  • 89 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2013.

Based on Mason Street Advisors's 13F filing for Q3 2013, filed 14 Nov 2013.